GB2384426A - Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-α-Methyl dopa, acrylic or methacrylic - Google Patents
Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-α-Methyl dopa, acrylic or methacrylicInfo
- Publication number
- GB2384426A GB2384426A GB0111066A GB0111066A GB2384426A GB 2384426 A GB2384426 A GB 2384426A GB 0111066 A GB0111066 A GB 0111066A GB 0111066 A GB0111066 A GB 0111066A GB 2384426 A GB2384426 A GB 2384426A
- Authority
- GB
- United Kingdom
- Prior art keywords
- poly
- dopa
- methacrylic acid
- carbidopa
- acrylic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 title abstract 6
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 6
- 229920001577 copolymer Polymers 0.000 title abstract 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 title abstract 5
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 title abstract 5
- 238000013270 controlled release Methods 0.000 title abstract 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 title 2
- 125000005395 methacrylic acid group Chemical group 0.000 title 1
- -1 poly(acrylic acid) Polymers 0.000 abstract 8
- 229960004205 carbidopa Drugs 0.000 abstract 7
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 5
- 229920002845 Poly(methacrylic acid) Polymers 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 229920002125 Sokalan® Polymers 0.000 abstract 2
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 230000003276 anti-hypertensive effect Effects 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000005660 chlorination reaction Methods 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 230000001079 digestive effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to site directed drug delivery systems providing a controlled release of L-dopa, carbidopa, L- a -methyldopa and/or their combinations which eliminates or at least reduces the deleterious side effects of these drugs. Biologically active copolymers having directional characteristics to the digestive mucous tissue comprise L-dopa, carbidopa or L- a -methyldopa chemically combined with biologically acceptable poly(acrylic acid) or poly(methacrylic acid). The copolymers are obtained by a process comprising the steps of: (a) reacting L-dopa, carbidopa or L- a -methyldopa with a chlorination agent; (b) bringing into reaction the product of step (a) and poly(acrylic acid) or poly(methacrylic acid) in the presence of a suitable catalyst; (c) washing the copolymer obtained in step (b) with a suitable organic solvent and drying it until constant weight. Controlled release antihypertensive pharmaceuticals comprise at least one biologically active copolymer selected from the group consisting of poly(acrylic acid/L- a -methyldopa), poly(methacrylic acid/L-$G(a)-methyldopa), poly(acrylic acid/carbidopa), poly(methacrylic acid/carbidopa) or combinations thereof and a pharmaceutically acceptable vehicle. Controlled release pharmaceuticals comprising at least one biologically active copolymer selected from the group consisting of poly(acrylic acid/L-dopa), poly(methacrylic acid/L-dopa), poly(acrylic acid/carbidopa), poly(methacrylic acid/carbidopa) or combinations thereof and a pharmaceutically acceptable vehicle are used in the therapeutic treatment of Parkinson syndrome.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR9903382-8A BR9903382A (en) | 1999-08-04 | 1999-08-04 | Copolymers of acrylic or methacrylic acid / l-dopa, acrylic or methacrylic acid / l- <244> methyldopa or acrylic or methacrylic acid / l-carbidopa, process of obtaining it and drug compositions containing the same |
| PCT/BR2000/000086 WO2001010378A2 (en) | 1999-08-04 | 2000-08-02 | Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB0111066D0 GB0111066D0 (en) | 2001-06-27 |
| GB2384426A true GB2384426A (en) | 2003-07-30 |
Family
ID=4073069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0111066A Withdrawn GB2384426A (en) | 1999-08-04 | 2000-08-02 | Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-α-Methyl dopa, acrylic or methacrylic |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1117370A1 (en) |
| AU (1) | AU6142600A (en) |
| BR (1) | BR9903382A (en) |
| CA (1) | CA2346291A1 (en) |
| DE (1) | DE10082749T1 (en) |
| GB (1) | GB2384426A (en) |
| WO (1) | WO2001010378A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1697481A2 (en) * | 2003-12-09 | 2006-09-06 | Spherics, Inc. | Bioadhesive polymers with catechol functionality |
| WO2006026504A2 (en) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Mucoadhesive oral formulations of high permeability, high solubility drugs |
| JP2008516893A (en) * | 2004-08-27 | 2008-05-22 | スフェリックス，インク． | Multilayer tablets and bioadhesive dosage forms |
| US20060045865A1 (en) * | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| WO2007002318A2 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Bioadhesive polymers |
| EP2324810B1 (en) | 2009-11-19 | 2014-10-29 | Ivoclar Vivadent AG | Filled dental material based on polymerisable dihydroxyphenylalanine derivatives |
| CN117919217A (en) * | 2022-10-14 | 2024-04-26 | 浙江华海药业股份有限公司 | Pharmaceutical composition for treating parkinsonism and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0359996A2 (en) * | 1988-08-22 | 1990-03-28 | Al Marzook United Commercial Co. | Synthetic amino acid-and/or peptide-containing graft copolymers |
| EP0506979A1 (en) * | 1990-10-24 | 1992-10-07 | Eisai Co., Ltd. | Organic polymer compound and production thereof |
-
1999
- 1999-08-04 BR BR9903382-8A patent/BR9903382A/en unknown
-
2000
- 2000-08-02 CA CA002346291A patent/CA2346291A1/en not_active Abandoned
- 2000-08-02 WO PCT/BR2000/000086 patent/WO2001010378A2/en not_active Application Discontinuation
- 2000-08-02 DE DE10082749T patent/DE10082749T1/en not_active Withdrawn
- 2000-08-02 AU AU61426/00A patent/AU6142600A/en not_active Abandoned
- 2000-08-02 EP EP00947704A patent/EP1117370A1/en not_active Withdrawn
- 2000-08-02 GB GB0111066A patent/GB2384426A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0359996A2 (en) * | 1988-08-22 | 1990-03-28 | Al Marzook United Commercial Co. | Synthetic amino acid-and/or peptide-containing graft copolymers |
| EP0506979A1 (en) * | 1990-10-24 | 1992-10-07 | Eisai Co., Ltd. | Organic polymer compound and production thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001010378A2 (en) | 2001-02-15 |
| EP1117370A1 (en) | 2001-07-25 |
| GB0111066D0 (en) | 2001-06-27 |
| BR9903382A (en) | 2001-03-20 |
| AU6142600A (en) | 2001-03-05 |
| WO2001010378A3 (en) | 2001-08-30 |
| DE10082749T1 (en) | 2001-11-22 |
| CA2346291A1 (en) | 2001-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kurakula et al. | Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition | |
| CN102076331B (en) | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | |
| Debotton et al. | Applications of polymers as pharmaceutical excipients in solid oral dosage forms | |
| CA2444561A1 (en) | Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation | |
| WO1999053943A3 (en) | Therapeutic angiogenic factors and methods for their use | |
| AU7522601A (en) | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | |
| WO2007000778A3 (en) | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof | |
| HUP0203123A2 (en) | Process for preparation of polyglutamate-therapeutic agent conjugates | |
| WO2005079861A3 (en) | Polymeric water soluble prodrugs | |
| CA2452806A1 (en) | Water-soluble stabilized self-assembled polyelectrolytes | |
| CN102516417A (en) | Cyclodextrin-based polymers for therapeutics delivery | |
| ATE235895T1 (en) | DRUG DELIVERY SYSTEM CONTAINING A HARD-PACKED, SOLID DRUG BASE | |
| DE60223499D1 (en) | TERMINAL BRANCHED, POLYMER LEFT, AND POLYMER CONJUGATES THEREOF | |
| EP1032605A4 (en) | Polyanhydrides with therapeutically useful degradation products | |
| CY1108165T1 (en) | LOCAL USE OF NF-κB BATTERY FOR THE TREATMENT OF TREATMENT OF ATOPHIC SKIN | |
| TR200200518T2 (en) | Farmological Formulations Used in the Prevention of Stroke, Diabetes and / or Congestive Heart Failure | |
| ATE438389T1 (en) | MIXING SYSTEM FOR PROVIDING SOLUBILITY OF PHARMACEUTICAL ACTIVE INGREDIENTS IN POLYMER MATRICES | |
| WO2005016867A3 (en) | Anthranilic acid derivatives and their use as activators of the hm74a receptor | |
| GB2384426A (en) | Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-α-Methyl dopa, acrylic or methacrylic | |
| CN108697640A (en) | A kind of hydrogel that can be degraded in physiological conditions | |
| Nho et al. | Preparation, properties and biological application of pH-sensitive poly (ethylene oxide)(PEO) hydrogels grafted with acrylic acid (AAc) using gamma-ray irradiation | |
| PL364801A1 (en) | Taste masked compositions | |
| WO2003041656A3 (en) | Soluble drug extended release system | |
| WO2006047714A3 (en) | Sustained release of active molecules from polymers topically applied to skin or hair | |
| WO2005056520A8 (en) | Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |